Skip to main content

Table 1 Demographic characteristics and disease severities of ICU patients with nosocomial pneumonia treated with and without add-on tigecycline in combination regimens

From: Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study

 

All cases

Add-on tigecycline

 

Yes

No

Case number

395

148

247

 

Mean age (SD)

70.0 (15.7)

70.6 (13.6)

69.7 (16.9)

0.552

Male

261 (66.1%)

98 (66.2%)

163 (66.0%)

0.964

Mean BMI (SD)

23.0 (4.5)

23.2 (4.9)

22.8 (4.2)

0.347

Smoking history

151 (38.2%)

59 (39.9%)

92 (37.2%)

0.604

Alcohol consumption

67 (17.0%)

27 (18.2%)

40 (16.2%)

0.599

Isolated pathogens

0.087

 CRAB

321 (81.3%)

128 (86.5%)

193 (78.1%)

 

 CRE

74 (18.7%)

20 (13.6%)

54 (21.8%)

 

Pneumonia types

0.574

 HAP

116 (29.4%)

41 (27.7%)

75 (30.4%)

 

 VAP

279 (70.6%)

107 (72.3%)

172 (69.6%)

 

ICU types

0.190

 Medical ICU

281 (71.1%)

111 (75.0%)

170 (68.8%)

 

 Surgical ICU

114 (28.9%)

37 (25.0%)

77 (31.2%)

 

Comorbidities

 Malignancies

54 (13.7%)

16 (10.8%)

38 (15.4%)

0.200

 Renal insufficiency

39 (9.9%)

15 (10.1%)

24 (9.7%)

0.893

 Chronic lung diseases

71 (18.0%)

28 (18.9%)

43 (17.4%)

0.705

 Diabetes

139 (35.2%)

59 (39.9%)

80 (32.4%)

0.132

 Autoimmune disease

18 (4.6%)

10 (6.8%)

8 (3.2%)

0.105

Intravenous antibiotics

 Colistin

167 (42.3%)

64 (43.2%)

103 (41.7%)

0.764

 Sulbactam

138 (34.9%)

28 (18.9%)

110 (44.5%)

< 0.001

 Carbapenem

156 (39.5%)

58 (39.2%)

98 (39.7%)

0.924

Antibiotics susceptibility

 Sulbactam resistance

99 (25.1%)

47 (31.8%)

52 (21.1%)

0.017

 Colistin resistance

3 (0.8%)

2 (1.4%)

1 (0.4%)

0.563

APACHE II scoresa (median, IQR)

23 (18–27)

22 (17–27)

23 (18–27)

0.098

SOFA scores (median, IQR)

 ICU admission

8 (5–10)

8 (6–11)

7 (5–10)

0.013

 Pneumonia index date

8 (5–10)

8 (6–11)

7 (5–10)

0.090

Presenting featuresb

 Septic shock

65 (16.5%)

29 (19.6%)

36 (14.6%)

0.193

 Invasive ventilator

364 (92.2%)

141 (95.3%)

223 (90.3%)

0.074

 PF ratio < 200

109 (27.6%)

38 (25.7%)

71 (28.7%)

0.509

 Dialysisc

47 (11.9%)

18 (12.2%)

29 (11.7%)

0.900

Laboratory resultsd (median, IQR)

 Leukocytes (× 109 per L)

12.5 (8.3–16.6)

12.8 (8.7–18.6)

12.3 (8.2–16.1)

0.194

 Albumin (g/dL)

2.7 (2.3–3.0)

2.6 (2.2–2.9)

2.7 (2.4–3.1)

< 0.001

 CRP (mg/dL)

8.6 (5.1–15.0)

8.6 (5.6–15.7)

8.6 (4.9–14.8)

0.500

Tigecycline (median, IQR)

 Daily dosage

  200 mg

6 (4.1%)

6 (4.1%)

–

–

  100 mg

142 (95.9%)

142 (95.9%)

–

–

 Treatment duration (days)

–

7 (6–14)

–

–

  1. Data are presented as n (%)
  2. APACHE II Acute Physiology and Chronic Health Evaluation II, BMI body mass index, CRP carbapenem-resistant Pseudomonas aeruginosa, CRAB carbapenem-resistant Acinetobacter baumannii, CRE carbapenem-resistant Enterobacteriaceae, HAP hospital-acquired pneumonia, ICU intensive care unit, IQR interquartile range, PF ratio PaO2/FiO2 ratio, SD standard deviation, SOFA Sequential Organ Failure Assessment, VAP ventilator-associated pneumonia
  3. aObtained on ICU admission date
  4. bPresence of organ dysfunction on pneumonia index date
  5. cIncluding hemodialysis and continuous venovenous hemofiltration
  6. dObtained on pneumonia index date
Back to article page

Journal of Intensive Care

ISSN: 2052-0492